Categories
  • Semaglutide Impurities, des-26-Leu-SMT
  • Semaglutide Impurities, des-26-Leu-SMT

Semaglutide Impurities, des-26-Leu-SMT

The semaglutide impurity des-26-Leu-SMT is a structural analog that may be produced during the synthesis or degradation of the GLP-1 analog semaglutide. It is characterized by the absence of the 26th leucine (Leu) residue, which may lead to changes in molecular activity or stability. This impurity needs to be strictly monitored in drug quality control to ensure the safety and efficacy of semaglutide preparations.

  • Product Details

  • Technical Support

Product Overview

Basic Description

Structure and function:
1. des-26-Leu-SMT is an impurity of semaglutide that lacks the leucine residue at position 26.
2. It is a GLP-1 receptor agonist that regulates blood glucose levels by mimicking intestinal secretion of glucagon-like peptide-1 (GLP-1).
3. Due to the lack of an amino acid residue, its biological activity and pharmacokinetic properties may differ from those of semaglutide.
In vitro and in vivo studies:
1. In vitro studies have shown that des-26-Leu-SMT is still able to bind to and activate the GLP-1 receptor, but its affinity and potency may be reduced.
2. In vivo studies have shown that the hypoglycemic effect of this impurity in animal models is weaker than that of semaglutide, and its half-life may be shorter.
3. Preclinical studies have shown that des-26-Leu-SMT may cause adverse reactions or reduced efficacy in some cases.

​Three-letter sequence​

H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Asp-Val-Arg-Arg-Arg-Arg-Arg-Arg-Gly-CONH2

​Single letter sequence​

HHAEGTFTSDVSSYLEGQAAKEFIAWLVKGDVRRAARRRRG-NH2

Molecular formula

C184H284N51O56S

Molecular weight

4034.16 g/mol

Product Attributes

purity

>98%

form

Lyophilized powder

Storage conditions

Store at -20°C/-80°C away from light


Instructions
  • Please store the product immediately according to the recommended conditions in the instructions upon receipt. Unless otherwise specified, all products are freeze-dried powders. Since trace amounts of peptides are deposited in the tube during the freeze-drying process, forming a very thin or invisible peptide layer, we recommend centrifuging at about 8,000-12,000g for 10-30 seconds in a centrifuge before opening the tube cap, so that the peptides attached to the tube cap or tube wall are aggregated at the bottom of the tube.
  • Please refer to relevant literature for the specific optimal working concentration, or explore and optimize through experiments based on the purpose of the experiment and specific cells and animals.
Our company can provide customized synthesis of high-polypeptide, virtual screening of compounds, Animal disease model construction,
Drug safety verification,
Application technology support for gene editing animals, etc.
For specific application consultation, please contact the sales department.

We look forward to your inquiries:

Sales Department 1: Manager Han
Mobile phone: 18701856899
WeChat: 18701856899
QQ: 1295139147
Email: 18701856899@163.com